Genetic analysis of MMP gene polymorphisms in patients with Kawasaki disease

Pediatric Research

Volumn 63, Issue 2, 2008, Pages 182-185

  Ikeda, Kazuyuki ^a,c   Ihara, Kenji ^a   Yamaguchi, Kenichiro ^a   Muneuchi, Jun ^a   Ohno, Takuro ^a   Mizuno, Yumi ^b   Hara, Toshiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA CHILDREN S HOSPITAL   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; COLLAGENASE 3; GELATINASE B; IMMUNOGLOBULIN; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; STROMELYSIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENOTYPE; HAPLOTYPE; HUMAN; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; CHILD; CORONARY ARTERY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASES; MUCOCUTANEOUS LYMPH NODE SYNDROME; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 38349093967     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/PDR.0b013e31815ef224     Document Type: Article

References (28)

1. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF 1995 The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 96:1057-1061
2. Muta H, Ishii M, Egami K, Furui J, Sugahara Y, Akagi T, Nakamura Y, Yanagawa H, Matsuishi T 2004 Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr 144:496-499
3. Burns JC, Glode MP 2004 Kawasaki syndrome. Lancet 364:533-544
4. Maeno N, Takei S, Masuda K, Akaike H, Matsuo K, Kitajima I, Maruyama I, Miyata K 1998 Increased serum levels of vascular endothelial growth factor in Kawasaki disease. Pediatr Res 44:596-599
5. Ohno T, Igarashi H, Inoue K, Akazawa K, Joho K, Hara T 2000 Serum vascular endothelial growth factor: a new predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr 159:424-429
6. Ohno T, Yuge T, Kariyazono H, Igarashi H, Joh-o K, Kinugawa N, Kusuhara K, Hara T 2002 Serum hepatocyte growth factor combined with vascular endothelial growth factor as a predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr 161:105-111
7. Takeshita S, Tokutomi T, Kawase H, Nakatani K, Tsujimoto H, Kawamura Y, Sekine I 2001 Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clin Exp Immunol 125:340-344
8. Kariyazono H, Ohno T, Khajoee V, Ihara K, Kusuhara K, Kinukawa N, Mizuno Y, Hara T 2004 Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease. Pediatr Res 56:953-959
9. Breunis WB, Biezeveld MH, Geissler J, Ottenkamp J, Kuipers IM, Lam J, Hutchinson A, Welch R, Chanock SJ, Kuijpers TW 2006 Vascular endothelial growth factor gene haplotypes in Kawasaki disease. Arthritis Rheum 54:1588-1594
10. Thornton S 2006 Contribution of angiogenic genes to the complex genetic trait underlying Kawasaki disease. Arthritis Rheum 54:1361-1365
11. Furuno K, Takada H, Yamamoto K, Ikeda K, Ohno T, Khajoee V, Mizuno Y, Hara T 2007 Tissue inhibitor of metalloproteinase 2 and coronary artery lesions in Kawasaki disease. J Pediatr 151:155-160
12. Park JA, Shin KS, Kim YW 2005 Polymorphism of matrix metalloproteinase-3 promoter gene as a risk factor for coronary artery lesions in Kawasaki disease. J Korean Med Sci 20:607-611
13. Ye S 2006 Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 69:636-645
14. Ogata T, Shibamura H, Tromp G, Sinha M, Goddard KA, Sakalihasan N, Limet R, MacKean GL, Arthur C, Sueda T, Land S, Kuivaniemi H 2005 Genetic analysis of polymorphisms in biologically relevant candidate genes in patients with abdominal aortic aneurysms. J Vasc Surg 41:1036-1042
15. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D 2004 Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 64:7622-7628
16. Akagi T, Rose V, Benson LN, Newman A, Freedom RM 1992 Outcome of coronary artery aneurysms after Kawasaki disease. J Pediatr 121:689-694
17. Wang Y, Fang S, Wei L, Wang R, Jin X, Wen D, Li Y, Guo W, Wang N, Zhang J 2005 No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma. Lung Cancer 49:155-161
18. Lewontin RC 1995 The detection of linkage disequilibrium in molecular sequence data. Genetics 140:377-388
19. Sternlicht MD, Werb Z 2001 How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463-516
20. Woessner JF Jr 1991 Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145-2154
21. Knox JB, Sukhova GK, Whittemore AD, Libby P 1997 Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 95:205-212
22. Stetler-Stevenson WG 1996 Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 148:1345-1350
23. Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Nakano H, Nagasaka H, Sasaki N, Asano H, Kyo S, Yokote Y 2001 Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation 104:860-863
24. Gavin PJ, Crawford SE, Shulman ST, Garcia FL, Rowley AH 2003 Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol 23:576-581
25. Baker AH, Edwards DR, Murphy G 2002 Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115:3719-3727
26. Karagiannis ED, Popel AS 2004 A theoretical model of type I collagen proteolysis by matrix metalloproteinase (MMP) 2 and membrane type 1 MMP in the presence of tissue inhibitor of metalloproteinase 2. J Biol Chem 279:39105-39114
27. Yoon S, Kuivaniemi H, Gatalica Z, Olson JM, Buttice G, Ye S, Norris BA, Malcom GT, Strong JP, Tromp G 2002 MMP13 promoter polymorphism is associated with atherosclerosis in the abdominal aorta of young black males. Matrix Biol 21:487-498
28. Mao D, Lee JK, VanVickle SJ, Thompson RW 1999 Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smooth muscle cells in culture. Biochem Biophys Res Commun 261:904-910